Drug Trial Radar · NCT06169319
A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)
Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
231
Actual
Start
Jan 3, 2024
Primary completion
Sep 30, 2024
Study completion Sep 30, 2024
Sponsor
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics CompanyIndustry
- Sponsor type
- Industry
- First posted
- Dec 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy, safety, and tolerability of 2 different doses of collagenase clostridium histolyticum (CCH) (previously known as EN3835) compared to placebo.
Conditions
- Plantar Fasciitis
Interventions
Collagenase Clostridium Histolyticum (CCH)Biological
Biologic: Intrafascial injection
PlaceboBiological
Intrafascial injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline at Week 12 in the Weekly Mean of the Average Daily (24-hour) Pain (ADP) Score as Measured on the Pain Intensity Numeric Rating Scale (NRS)Time frame: Baseline, Week 12
Locations
39 sites in 1 country. Site status is shown where the registry gives one.
Endo Site 8
Tucson, Arizona
Endo Site 20
Castro Valley, California
Endo Site 13
Corona, California
Endo Site 6
Encinitas, California
Endo Site 11
Fresno, California
Endo Site 16
Los Angeles, California
Endo Site 40
Los Angeles, California
Endo Site 21
San Francisco, California
Endo Site 10
Tarzana, California
Endo Site 37
Coconut Creek, Florida
Endo Clinical Site 3
Pinellas Park, Florida
Endo Site 14
Sweetwater, Florida
Endo Site 7
Lawrenceville, Georgia
Endo Site 23
Stonecrest, Georgia
Endo Site 31
North Chicago, Illinois
Endo Site 28
O'Fallon, Illinois
Endo Site 33
Overland Park, Kansas
Endo Site 35
Shreveport, Louisiana
Endo Clinical Site 2
Pasadena, Maryland
Endo Site 19
Grand Rapids, Michigan
Endo Site 27
Missoula, Montana
Endo Site 38
Westwood, New Jersey
Endo Site 25
Moore, Oklahoma
Endo Site 39
Portland, Oregon
Endo Site 36
Malvern, Pennsylvania
Endo Clinical Site 4
Bedford, Texas
Endo Site 24
Burleson, Texas
Endo Site 17
Dallas, Texas
Endo Site 26
Dallas, Texas
Endo Site 18
Dallas, Texas
Endo Site 30
Fort Worth, Texas
Endo Clinical Site 1
Georgetown, Texas
Endo Site 15
Houston, Texas
Endo Site 9
McAllen, Texas
Endo Site 34
San Antonio, Texas
Endo Site 22
San Antonio, Texas
Endo Clinical Site 5
Salt Lake City, Utah
Endo Site 32
Newport News, Virginia
Endo Site 12
Suffolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.